{"id":"arxiv:2301.05473","kind":"article","title":"A phenotype-structured model for the tumour-immune response","authors":["Zineb Kaid","Camille Pouchol","Jean Clairambault"],"author_count":3,"year":2023,"published":"2023-01-13","venue":"Mathematical Modelling of Natural Phenomena","cited_by":7,"doi":"10.1051/mmnp/2023025","arxiv_id":"2301.05473","nct_id":null,"source_url":"https://arxiv.org/abs/2301.05473","archive_url":"https://space-kitty.com/papers/arxiv:2301.05473","updated":"2023-08-31","pmid":null,"pmcid":null,"openalex_id":"W4316096538","pdf_url":"https://arxiv.org/pdf/2301.05473","abstract":"This paper presents a mathematical model for tumour-immune response interactions in the perspective of immunotherapy by immune checkpoint inhibitors ICIs. The model is of the nonlocal integro-differential Lotka-Volterra type, in which heterogeneity of the cell populations is taken into account by structuring variables that are continuous internal traits (aka phenotypes) present in each individual cell. These represent a lumped ``aggressiveness'', i.e., for tumour cells, malignancy understood as the ability to thrive in a viable state under attack by immune cells or drugs - which we propose to identify as a potential of de-differentiation -, and for immune cells, ability to kill tumour cells, in other words anti-tumour efficacy. We analyse the asymptotic behaviour of the model in the absence of treatment. By means of two theorems, we characterise the limits of the integro-differential system under an a priori convergence hypothesis. We illustrate our results with a few numerical simulations, which show that our model reproduces the three Es of immunoediting: elimination, equilibrium, and escape. Finally, we exemplify the possible impact of ICIs on these three Es.","abstract_license":"CC0-1.0 (arXiv descriptive metadata)","license":null,"is_open_access":false,"retracted":false,"peer_reviewed":null,"categories":["math.AP","q-bio.CB"],"details":null,"provenance":"arxiv","attribution":"Abstract: arXiv descriptive metadata (CC0). Thank you to arXiv for use of its open access interoperability. This service was not reviewed or approved by, nor does it necessarily express or reflect the policies or opinions of, arXiv.","topics":[{"slug":"cancer-immunotherapy","name":"Cancer Immunotherapy","domain_slug":"medicine"}],"cited_in_dossiers":[]}